Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal

Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent".  Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coexistence of AR-dependent and AR-independent tumor clones. AR-targeted agents (abiraterone acetate, enzalutamide) and taxanes (docetaxel (DOC), cabazitaxel - specifically developed to overcome DOC resistance) are the backbone of mCRPC therapy. The rising concern of cross-resistance between mCRPC therapies and the evidence that some patients may not respond to all available drugs have increased the complexity of managing mCRPC. This Phase 4 trial was designed to help define the optimal sequence of therapies to optimize patient outcomes involving 79 sites in 12 European countries.   Ronald de Wit, MD, Ph.D., of Erasmus Medical Center in Rotterdam, the Netherlands presented the results of the CARD trial at the recent 2019 European Society for Medical Oncology (ESMO) annual meeting in Barcelona, Spain. The results were simultaneously published in the New England Journal of Medicine.  The conclusions of the trial indicate that switching to cabazitaxel instead of another androgen receptor-signaling inhibitor improved survival in men with metastatic castration-resistant prostate cancer (CRPC) who progressed on docetaxel and one of the newer androgen-blocking agents. 


Bertrand Tombal, MD, Ph.D., Professor and Chair, Université Catholique de Louvain, Brussels, Belgium

Thomas Keane, MBBCh, FRCSI, FACS, Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, South Carolina. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.